The biocides manufactured by Hexi Pharma do not meet the minimum efficiency standards and have no effect even in controlled laboratory conditions, and their questionable effect has ensured conditions for the development of antimicrobial resistance in hospitals, the indictment prepared by the Prosecutors General’s Office reads.
“The biocides manufactured by SC Hexi Pharma CO SRL do not meet the minimum efficiency standards, as shown by the many tests carried out. The use of SC Hexi Pharma CO SRL biocides does not produce the expected results even under controlled laboratory conditions, much less in a medical unit, where a strict control of the areas where the biocides are used cannot be strictly controlled,” the prosecutors say.
Prosecutors explain that substances sold to hospitals were inadequate, both in terms of indication on the label on the concentration of the active substance and in terms of their efficiency.
“This combination of factors was detrimental to the health system in Romania,” reads the indictment.
During June 1, 2010 – May 16, 2016 Hexi Pharma produced and marketed to numerous hospitals 41 biocide products of main group 1, of which 39 were sold to 340 hospitals and were non-compliant in terms of concentration of the active substances and of biocide efficiency.
Prosecutors also show that Hexi Pharma’s overall activity “has been subsumed to criminal purpose” upon the initiative and under the organization of Dan Condrea (deceased on May 22, 2016), who held 97% stake in the company.
Two days ago, the prosecutor have sent to court the Hexi Pharma diluted disinfectants file, after less than a year since the investigation started, for 340 crimes of fraud, use of forgery and indirect participation in committing the crime of preventing fight against diseases. The company is investigated for fraud and for jeopardizing the public health after it allegedly sold diluted disinfectants to hundreds of hospitals in Romania.